Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: A multicentre retrospective observational study from the UK

Multiple Sclerosis Journal

Volumn 20, Issue 11, 2014, Pages 1533-1540

  Elsone, Liene ^a   Kitley, Joanna ^b   Luppe, Sebastian ^c   Lythgoe, Daniel ^d   Mutch, Kerry ^a   Jacob, Saiju ^e   Brown, Rachel ^b   Moss, Kathryn ^f   McNeillis, Benjamin ^b   Goh, Yee Yen ^a   Leite, M Isabel ^b   Robertson, Neil ^c   Palace, Jackie ^b   Jacob, Anu ^a  

^a THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^f ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

aquaporin 4; azathioprine; Neuromyelitis optica; NMO; retention; tolerability

Indexed keywords

AMYLASE; AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLATIRAMER; LEFLUNOMIDE; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID; NATALIZUMAB; PREDNISOLONE; RITUXIMAB; STEROID; TROPONIN; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AMYLASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPIRATION PNEUMONIA; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COHORT ANALYSIS; DEATH; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG RETENTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HAIR LOSS; HEART INFARCTION; HEART RIGHT VENTRICLE FAILURE; HERPES ZOSTER; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; LEUKOCYTOSIS; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEGALOCYTOSIS; MYALGIA; MYELOOPTIC NEUROPATHY; NERVOUS SYSTEM FUNCTION; NEUTROPENIA; NEUTROPHILIA; OBSERVATIONAL STUDY; PANCYTOPENIA; PHENOTYPE; PREGNANCY; RECURRENCE RISK; RELAPSE; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; STEROID THERAPY; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNITED KINGDOM; ANEMIA; CARDIOPULMONARY INSUFFICIENCY; CONTROLLED STUDY; DRUG SAFETY; FEVER; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEMATOLOGIC DISEASE; MORTALITY; NAUSEA; VOMITING; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEUROMYELITIS OPTICA; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

ADULT; AGED; AQUAPORIN 4; AZATHIOPRINE; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; RECURRENCE; RETROSPECTIVE STUDIES; TIME; TREATMENT OUTCOME;

EID: 84906791521     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514525870     Document Type: Article

References (39)

1. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008 ; 70: 2197-2200
2. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006 ; 59: 566-569
3. Mandler RN, Ahmed W, Dencoff JE.. Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998 ; 51: 1219-1220
4. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, et al. Neuromyelitis optica treatment: Analysis of 36 patients. Arch Neurol. 2010 ; 67: 1131-1136
5. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011 ; 77: 659-666
6. Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: A retrospective analysis. Mult Scler. 2007 ; 13: 968-974
7. Sahraian MA, Moinfar Z, Khorramnia S, et al. Relapsing neuromyelitis optica: Demographic and clinical features in Iranian patients. Eur J Neurol. 2010 ; 17: 794-799
8. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology. 2008 ; 71: 93-100
9. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients. Arch Neurol. 2009 ; 66: 1128-1133
10. Kim SH, Kim W, Park MS, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol. 2011 ; 68: 473-479
11. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006 ; 63: 957-963
12. Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013 ; 84: 918-921
13. Minagar A, Sheremata WA. Treatment of Devic's disease with methotrexate and prednisone. Int J MS Care. 2000 ; 2: 43-49
14. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol. 2008 ; 65: 1443-1448
15. Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011 ; 68: 1412-1420
16. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011 ; 76: 1310-1315
17. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005 ; 64: 1270-1272
18. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: Creating strategies for therapeutic success. Mult Scler. 2012 ; 18: 1022-1026
19. Ip VH, Lau AY, Au LW, et al. Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci. 2013 ; 324: 38-39
20. Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011 ; 17: 1225-1230
21. Magraner MJ, Coret F, Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica [article in English and Spanish]. Neurologia. 2013 ; 28: 65-72
22. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study. Lancet Neurol. 2013 ; 12: 554-562
23. Kieseier BC, Stüve O, Dehmel T, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: Implication for cellular immune responses. JAMA Neurol. 2013 ; 70: 390-393
24. Ayzenberg I, Kleiter I, Schroder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 2013 ; 70: 394-397
25. Araki M, Aranami T, Matsuoka T, et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. 2013 ; 23: 827-831
26. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 ; 64: 753-767
27. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992 ; 43: 329-339
28. Palace J, Leite MI, Jacob A. A practical guide to the treatment of neuromyelitis optica. Pract Neurol. 2012 ; 12: 209-214
29. Baker KB, Spurrier NJ, Watkins AS, et al. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Br J Ophthalmol. 2006 ; 90: 1481-1485
30. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66: 1485-1489
31. Pinto AL, Chebli LA, Ribeiro MS, et al. Azathioprine therapy in steroid-dependent patients with Crohn disease: Results of a 10-year longitudinal follow-up study. Med Sci Monit. 2009 ; 15: PI19 - PI26
32. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2010 ; 6: CD000545
33. Oglesby A, Shaul AJ, Pokora T, et al. Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: A systematic literature review. Int J Rheumatol. 2013 ; 2013: 347520
34. Chaparro M, Ordás I, Cabré E, et al. Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013 ; 19: 1404-1410
35. Timmer A, McDonald JW, Tsoulis DJ, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012 ; 9: CD000478
36. Cristelli MP, Tedesco-Silva H, Medina-Pestana JO, et al. Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids. Transpl Infect Dis. 2013 ; 15: 369-378
37. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999 ; 53: 1107-1114
38. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012 ; 135 (Pt 6). 1834-1849
39. London, GB: Pharmaceutical Press ; 2013 :